Scarica l'app Stockscreener
28.33
1.76%
0.49
Dopo l'orario di chiusura:
28.40
0.07
+0.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$27.84
Aprire:
$26.95
Volume 24 ore:
5.00M
Relative Volume:
0.80
Capitalizzazione di mercato:
$20.28B
Reddito:
$13.31M
Utile/perdita netta:
$-1.01B
Rapporto P/E:
-24.24
EPS:
-1.1685
Flusso di cassa netto:
$-766.86M
1 W Prestazione:
+3.58%
1M Prestazione:
+0.82%
6M Prestazione:
+77.28%
1 anno Prestazione:
+181.05%
Intervallo 1D:
$26.62
$28.55
Intervallo di 1 settimana:
$25.95
$28.55
Portata 52W:
$8.73
$30.33
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
28.33 | 20.28B | 13.31M | -1.01B | -766.86M | -1.1685 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-20 | Iniziato | Bernstein | Outperform |
| 2025-09-02 | Iniziato | Citigroup | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data UpdateSlideshow (NASDAQ:ROIV) 2026-04-04 - Seeking Alpha
ROIV PE Ratio & Valuation, Is ROIV Overvalued - intellectia.ai
ROIV | Roivant Sciences Ltd. Common Executive Compensation - Quiver Quantitative
Roivant Sciences (ROIV) Is Up 6.8% After Mixed Autoimmune Trial UpdatesHas The Bull Case Changed? - simplywall.st
Roivant Sciences Ltd. (ROIV) stock price, news, quote and history - Yahoo Finance UK
Roivant Sciences Ltd. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Should Brepocitinib’s New Trials and Batoclimab’s Setback Require Action From Roivant Sciences (ROIV) Investors? - finance.yahoo.com
Roivant (NASDAQ: ROIV) executive settles RSU taxes with shares - Stock Titan
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP - finance.yahoo.com
Roivant Shrugs Off Batoclimab Phase III Failure in TED - Citeline News & Insights
Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint - finance.yahoo.com
Roivant (Nasdaq: ROIV) shows $4.3B cash and mixed late-stage trial results - Stock Titan
Scarring hair-loss disease gets drug trial with no approved therapy - Stock Titan
Roivant Sciences (ROIV) executive settles CVARs and RSUs into shares - Stock Titan
Roivant Sciences Ltd. (ROIV) Stock Forecasts - finance.yahoo.com
(ROIV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Movement Recap: Is Roivant Sciences Ltd forming a bullish divergence2026 Patterns & Long-Term Capital Growth Strategies - baoquankhu1.vn
CEO Change: Is Roivant Sciences Ltd a potential multi bagger2026 Pullbacks & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Volume Summary: Is Roivant Sciences Ltd stock risky to hold now2026 Retail & Community Consensus Stock Picks - baoquankhu1.vn
250,468 Shares in Roivant Sciences Ltd. $ROIV Acquired by Exchange Traded Concepts LLC - MarketBeat
Roivant Sciences Insider Sold Shares Worth $1,921,500, According to a Recent SEC Filing - MarketScreener
Roivant Sciences Ltd (ROIV) Stock Price Quote Today & Current Price Chart - Capital.com
Roivant Sciences Ltd (ROIV) Stock Price Quote Today & Current Price Chart | Capital.com Australia - capital.com
Roivant Sciences (NASDAQ: ROIV) director exercises 70K options, sells 70K shares - Stock Titan
Aug Sentiment: Is Roivant Sciences Ltd backed by strong institutional buyingStock Surge & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Assessing Roivant Sciences (ROIV) Valuation After Brepocitinib Priority Review And Phase 3 VALOR Success - Sahm
Cantor Fitzgerald reiterates Roivant Sciences stock rating By Investing.com - Investing.com India
Gains Recap: Should I hold or sell Roivant Sciences Ltd nowMarket Weekly Review & AI Driven Stock Movement Reports - baoquankhu1.vn
Sentiment Watch: Is Roivant Sciences Ltd a potential multi bagger2026 Decliners & High Accuracy Swing Entry Alerts - baoquankhu1.vn
ROIV Technical Analysis & Stock Price Forecast - intellectia.ai
Bernstein initiates coverage of Roivant Sciences Ltd. (ROIV) with an outperform rating - MSN
New England Journal of Medicine publishes positive phase 3 valor trial results of brepocitinib in dermatomyositis - marketscreener.com
NEJM study: rare muscle-skin disease drug beat placebo in Phase 3 - Stock Titan
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis - Sahm
Aug Ideas: Whats the fair value of Roivant Sciences Ltd stockTrade Exit Report & Community Verified Watchlist Alerts - baoquankhu1.vn
Should Roivant’s Moderna Settlement Shift Investor Focus to Pipeline Execution Risks for Roivant Sciences (ROIV)? - simplywall.st
Can Roivant Sciences Ltd sustain earnings growthEarnings Performance Report & AI Forecasted Stock Moves - baoquankhu1.vn
Big Money Moves: Can Roivant Sciences Ltd sustain earnings growthProduct Launch & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Vanguard realignment leads to separate reports for Roivant (ROIV) - Stock Titan
Bernstein Initiates Coverage of Roivant Sciences Ltd. (ROIV) with an Outperform Rating - Insider Monkey
Roivant Sciences (ROIV) CFO reports RSU tax-withholding of 1,546 shares - Stock Titan
Assenagon Asset Management S.A. Purchases 6,877,348 Shares of Roivant Sciences Ltd. $ROIV - marketbeat.com
12 Best UK Stocks to Buy According to Hedge Funds - Insider Monkey
Roivant Sciences, Genevant, Arbutus, and Moderna Settle International Patent Litigation – Key Terms and Confidentiality Details - Minichart
Roivant Sciences (ROIV) soars 19.4% as pipeline drugs progress - MSN
Roivant secures FDA priority review for dermatomyositis treatment - MSN
Risk Analysis: Is Roivant Sciences Ltd backed by strong institutional buyingBreakout Watch & High Conviction Investment Ideas - baoquankhu1.vn
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
(ROIV) Risk Channels and Responsive Allocation - Stock Traders Daily
Bernstein initiates Roivant Sciences stock with outperform rating By Investing.com - Investing.com Australia
Bernstein initiates Roivant Sciences stock with outperform rating - Investing.com
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.16%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):